Moderna: Argus research raises to buy from hold

On August 28, 2026, Argus Research upgraded its recommendation on Moderna (MRNA.US) from "Hold" to "Buy," signaling increased confidence in the company’s outlook. This move reflects a positive reassessment of Moderna’s strategic direction and potential for growth. The firm also raised its price target, indicating a belief in the company’s ability to deliver strong returns for investors.

The upgrade comes amid broader market optimism, particularly in the technology and software sectors, which have driven gains in major indices such as the Nasdaq, up 1.34% at midday. While Moderna operates in the biotechnology space, the overall market environment appears to be supportive of risk-on sentiment and innovation-driven equities.

Investors are advised to consider Argus’s revised stance in the context of Moderna’s recent performance and broader industry trends. As with any investment decision, due diligence and alignment with individual portfolio goals remain essential.